MedPath

Weight reduction by mazindol in morbid obesity with or without type 2 diabetes mellitus

Not Applicable
Conditions
obesity disease
Registration Number
JPRN-UMIN000027557
Lead Sponsor
Fukuoka University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with contraindication for administration of mazindol or SGLT2 inhibitor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Weight reduction rate in 3 months' administration of mazindol, with or without the use of SGLT2 inhibitor
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath